The safety of brodalumab for the treatment of psoriasis.
Helena IznardoLluis L PuigPublished in: Expert opinion on drug safety (2020)
Introduction: Brodalumab is a newly developed targeted biologic agent for the treatment of psoriasis that blocks IL-17 receptor A.Areas covered: This review sought to provide a detailed overview on safety of brodalumab for the treatment of psoriasis. A PubMed search was conducted for relevant literature. Here we review the efficacy and safety data from key phase II, phase III and open-label extension clinical trials, as well as systematic reviews and meta-analyses.Expert opinion: The unique mechanism of action of brodalumab offers advantages on efficacy over other targeted treatments, with a quick onset of action and long-term maintenance of treatment response. Brodalumab has a favorable safety profile, similar to other IL-17 inhibitors. Infections, especially mucocutaneous candidiasis, must be monitored. Suicidal ideation was detected in brodalumab trials, although a causal relationship has not been revealed. Brodalumab is a highly efficacious and comparably safe therapeutic choice in patients with moderate to severe psoriasis, especially when rapid control of the disease is desired.
Keyphrases
- clinical trial
- open label
- phase ii
- phase iii
- systematic review
- meta analyses
- randomized controlled trial
- cancer therapy
- combination therapy
- rheumatoid arthritis
- machine learning
- study protocol
- early onset
- atopic dermatitis
- phase ii study
- binding protein
- high intensity
- clinical practice
- drug delivery
- replacement therapy
- big data
- rectal cancer
- drug induced